A Non-interventional, Post-authorization Safety Study of Patients with Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden (CC-5013-MCL-005)

First published 02/05/2018

Last updated 07/03/2024

EU PAS number:

EUPAS23366

Study

Ongoing

Documents

Study protocol

Initial protocol

cc-5013-mcl-005-protamend5-0_redacted.pdf

English (4.28 MB - PDF) View document

Study results

Study report

Other information

Study, other information

CC-5013-MCL-005_Site List_10Jun2020

English (70.45 KB - PDF) View document

CC-5013-MCL-005_Site List_2022-05-16

English (96.49 KB - PDF) View document

Secondary tabs